Pancreatic Cancer Research

ResearcherHenry Ford HealthActive in the last 2 years

Vic Velanovich

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0133-948X; OpenAlex author ID A5043924393. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
2
Collaborators
30
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 3 papers

Papers 10

  1. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  2. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-25-0237↗
  3. Lifetime stressor exposure and depression among patients with pancreatic cancer: insights from the Florida Pancreas Collaborative. Co-author DOI 10.1186/s12885-025-15007-w↗
  4. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Co-author DOI 10.3389/fonc.2024.1362244↗
  5. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  6. An Evaluation of Artificial Neural Networks in Predicting Pancreatic Cancer Survival. First author DOI 10.1007/s11605-017-3518-7↗
  7. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Co-author DOI 10.1016/j.surg.2014.06.058↗
  8. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Last author DOI 10.1097/sla.0000000000000310↗
  9. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Last author DOI 10.1245/s10434-012-2736-1↗
  10. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. Last author DOI 10.1016/j.jamcollsurg.2012.05.021↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel K. Jeong · 3 shared papers, 2025 · strength 0.50
  2. José M. Pimiento · 3 shared papers, 2025 · strength 0.50
  3. Margaret A. Park · 3 shared papers, 2025 · strength 0.50
  4. Jennifer B. Permuth · 3 shared papers, 2025 · strength 0.50
  5. Kun Jiang · 2 shared papers, 2025 · strength 0.35
  6. Sarah M. Judge · 2 shared papers, 2025 · strength 0.31
  7. Nathan H. Parker · 2 shared papers, 2025 · strength 0.31
  8. Andrew R. Judge · 2 shared papers, 2025 · strength 0.31
  9. Dung‐Tsa Chen · 2 shared papers, 2025 · strength 0.31
  10. Evan W. Davis · 2 shared papers, 2025 · strength 0.31
  11. Paul A. Stewart · 2 shared papers, 2025 · strength 0.31
  12. J. Pablo Arnoletti · 2 shared papers, 2025 · strength 0.31
  13. Mokenge Peter Malafa · 2 shared papers, 2025 · strength 0.31
  14. Jason B. Fleming · 2 shared papers, 2025 · strength 0.31
  15. Jose Gilberto Trevino · 2 shared papers, 2025 · strength 0.31
  16. Sylvia L. Crowder · 2 shared papers, 2025 · strength 0.31
  17. Pamela Joy Hodul · 2 shared papers, 2025 · strength 0.31
  18. Ghulam Rasool · 2 shared papers, 2025 · strength 0.31
  19. Anthony DeSomma · 1 shared paper, 2025 · strength 0.19
  20. Dae Won Kim · 1 shared paper, 2025 · strength 0.19
  21. Mark Bloomston · 1 shared paper, 2025 · strength 0.19
  22. Robert C.G. Martin · 3 shared papers, 2012–2014 · strength 0.16
  23. Shaffer R. S. Mok · 1 shared paper, 2025 · strength 0.16
  24. for the Florida Pancreas Collaborative · 1 shared paper, 2025 · strength 0.16
  25. Dae Won Kim · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.